You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾-B(06185.HK)初段飆20%創近一個月高 旗下新冠疫苗獲納入WHO緊急使用清單
康希諾生物-B(06185.HK)旗下重組新型冠狀病毒疫苗(5型腺病毒載體)(商品名:克威莎)獲列入世衛(WHO)的緊急使用清單,今早(20日)大幅高開15%,報81.7元後,初段曾升20.3%,高見85.5元創近一個月高,隨後升幅略收窄,現升12%,報79.6元,成交219萬股,涉1.83億元。 WHO認為,克威莎符合世衛組織認定的防護新冠病毒的標準,且該疫苗帶來的好處遠大於風險。 其他涉足新冠疫苗開發及生產的醫藥股普遍跟隨大市上升,代理大中華區「復必泰」疫苗的復星醫藥(02196.HK)升1.7%、另由母企國藥集團提供新冠疫苗的國藥控股(01099.HK)亦升2%。另騰盛博藥-B(02137.HK)、開拓藥業-B(09939.HK)升0.9%至1.2%;歌禮-B(01672.HK)、石藥(01093.HK)、中生製藥(01177.HK)升1.8%至4%。惟三葉草生物-B(02197.HK)逆市跌3.7%。 主要CXO醫藥股亦上升,昭衍新藥(06127.HK)升2.5%,藥明生物(02269.HK)、藥明康德(02359.HK)及泰格醫藥(03347.HK)升3.3%至5.5%,方達控股(01521.HK)則升1.1%。 此外,內地新冠疫苗概念股智飛生物(300122.SZ)及康泰生物(300601.SZ)各升2%至3%、沃森生物(300142.SZ)升1.7%。 港股現升413點或約2.1%,報20,534點。成交335.16億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account